These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3865500)

  • 41. Oral intake of perphenazine decanoate.
    Larsen NE
    Ther Drug Monit; 1998 Dec; 20(6):724. PubMed ID: 9853996
    [No Abstract]   [Full Text] [Related]  

  • 42. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients.
    Levine J; Caspi N; Laufer N
    Schizophr Res; 1997 Jul; 26(1):55-63. PubMed ID: 9376337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
    Hansen LB; Larsen NE; Vestergård P
    Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ; Saxena B; Foley P; Grof P
    Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
    Prusoff BA; Williams DH; Weissman MM; Astrachan BM
    Arch Gen Psychiatry; 1979 May; 36(5):569-75. PubMed ID: 373665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study.
    Takahashi R; Inanaga K; Samejima K; Sarai K; Asada S; Otsuki S; Nakano S
    J Int Med Res; 1982; 10(4):257-67. PubMed ID: 6126413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
    Svestka J; Rysánek R; Náhunek K; Cesková E
    Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Chronic schizophrenia treated with depot perphenazine].
    Petersson H; Remvig J; Sorensen B
    Nord Psykiatr Tidsskr; 1971; 25(4):303-8. PubMed ID: 5154114
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
    Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
    Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-responsive symptoms during early neuroleptic treatment.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Psychiatry Res; 1992 Feb; 41(2):147-54. PubMed ID: 1574541
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
    Andersen TH; Bech P; Larsen NE
    Nord J Psychiatry; 2005; 59(3):205-8. PubMed ID: 16195121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
    Kane J; Quitkin F; Rifkin A; Klein DF
    Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical experiences with perphenazine enanthate].
    Rafter B
    Nord Psykiatr Tidsskr; 1971; 25(4):371-4. PubMed ID: 5154124
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of long-term sedation in cheetah (Acinonyx jubatus) with perphenazine enanthate and zuclopenthixol acetate.
    Huber C; Walzer C; Slotta-Bachmayr L
    J Zoo Wildl Med; 2001 Sep; 32(3):329-35. PubMed ID: 12785681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
    Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
    Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of perphenazine enanthate on open-field test behaviour and stress-induced hyperthermia in domestic sheep.
    Pedernera-Romano C; Ruiz de la Torre JL; Badiella L; Manteca X
    Pharmacol Biochem Behav; 2010 Jan; 94(3):329-32. PubMed ID: 19799930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Perphenazine enanthate in the treatment of chronic schizophrenia].
    Kampman R; Leppäluoto V
    Duodecim; 1970; 86(20):1167-70. PubMed ID: 5477736
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
    Viala A; Ba B; Durand A; Gouezo F; Hou N; Jørgensen A
    Psychopharmacology (Berl); 1988; 94(3):293-7. PubMed ID: 2895936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.